Chi­na-based drug­mak­er Hais­co Phar­ma­ceu­ti­cal has been on a deal­mak­ing tear this sum­mer, and its lat­est al­liance is with two dom­i­nant names in biotech.

The bio­phar­ma...

Af­ter a “com­pre­hen­sive eval­u­a­tion,” Bris­tol My­ers Squibb has pulled out of its part­ner­ship with Cel­lares and the cell ther­a­py man­u­fac­tur­er will re­struc­ture as a re­sult...

J&J’s Imaavy wins la­bel ex­pan­sion: The mon­o­clon­al an­ti­body is now the first treat­ment ap­provedspecif­i­cal­ly for warm au­toim­mune he­molyt­ic ane­mia, a rare au­toan­ti­body dis­ease that...

Bausch + Lomb’s dual-ac­tion drop for dry eye failed a Phase 2 study, the com­pa­ny ex­clu­sive­ly told End­points News on Mon­day. But CEO Brent Saun­ders claims...

Af­ter lengthy con­sid­er­a­tion, a DC fed­er­al judge on Mon­day re­ject­ed Mer­ck’s chal­lenge to Medicare drug price ne­go­ti­a­tions.

Judge Colleen Kol­lar-Kotel­ly of the US Dis­trict Court...